SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

June 9, 2020

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Latest News

Monkeypox Symptoms in London Patients Differ from Prior Outbreaks

How COVID-19 Infiltrates and Inflames the Heart

Top 5 Infectious Disease Stories of the Week: July 1, 2022

Communities With More Racial Prejudice Have Worse Health Outcomes

View More News